The financials
Stoke Therapeutics, Inc. by the numbers
Stoke Therapeutics, Inc. (STOK) reported revenue of $6.2M in Q1 2026 (quarter ended Mar 31, 2026), down 96% from the same quarter a year earlier. That came with net loss of $50M. For the full year FY2025, revenue was $184M (+405% year on year) and net income −$6.9M. Its largest product in Q1 2025 (quarter ended Mar 31, 2025) was IP License at $151M, 99% of the disclosed total, well ahead of Global Development Activity at 1.1%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $6.2M | $159M | −96% |
| Operating income | −$53M | $111M | to a loss |
| Net income | −$50M | $113M | to a loss |
| Diluted EPS | −$0.79 | $1.90 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| IP License | $151M | 99% |
| Global Development Activity | $1.6M | 1.1% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $4.0M (-32%)
Global Development Activity grew +146% year on yearIP License -100% year on year
Segment Latestquarter on quarteryear on year
- Global Development Activity$4.0M$4.0MQoQ -32%year on year +146%-32%+146%
- IP License$0.00$0.00QoQ -year on year -100%--100%